Annovis Bio (ANVS) investor relations material

Industry landscape and drug development trends

• Recent years have seen approvals of Alzheimer's drugs that slow cognitive decline rather than improve cognition, with over 180 studies ongoing and more novel drugs expected in the next 2–3 years.

• New therapies are focusing on oral availability, ease of administration, safety, and broader patient accessibility.

Mechanism of action and scientific rationale

• The presented drug targets four toxic proteins (plaque, tau, alpha synuclein, TDP-43) by inhibiting a homologous mRNA region, reducing their synthesis.

• Unlike existing drugs, it is both symptomatic and disease modifying, improving cognition short term and protecting nerve cells long term.

• The drug also reduces neuroinflammation by preventing nerve cell sickness and subsequent immune activation.

Preclinical and clinical results

• Animal studies in multiple models show the drug protects nerve cells from dying and improves axonal transport, supporting both symptomatic and disease-modifying effects.

• Early human studies in Alzheimer's patients showed statistically significant cognitive improvements over placebo, with larger studies confirming efficacy in early-stage subgroups.

• The drug demonstrated consistent benefits across demographics and worked on top of existing therapies.

• In Parkinson's disease, cognition was fully recovered in treated patients, with biomarker data supporting nerve cell health and reduced inflammation.